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A B S T R A C T
Uterine artery embolization can be regarded as a less invasive procedure for the treat-
ment of fibroids compared with myomectomy, hysterectomy, and laparoscopic myolysis.
The aim of this study was the evaluation of safety and efficacy of uterine artery emboli-
zation and of womens’ opinion about this treatment. After gynecological examination
sixty-nine premenopausal women underwent uterine artery embolization. All procedu-
res but four were technically successful; three women underwent unilateral emboliza-
tion because of vascular malformation and one of them had an allergic reaction to contrast
medium. Of the 69 patients: 58 went home the day after embolization, and 11 within first
week. The follow-up examinations after 3, 6 and 12 month showed a significant reduc-
tion of uterine and fibroid volume with significant improvement of bleeding. Therefore,
according to this report, uterine artery embolization is a successful, minimal invasive
treatment of myoma that preserves the uterus and requires shorter hospitalization and
recovery times than surgery.
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Introduction
Uterine leiomyomata (fibroids or myo-
mata), benign tumors of the human ute-
rus, are among the most common tumors
of women and can result in a host of prob-
lems: prolonged or heavy menstrual bleed-
ing, pelvic pressure or pain, or reproductive
dysfunction. The myomata are clinically
apparent in about 25% of women, and
they are the single most common indica-
tion for hysterectomy or myomectomy1,2.
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The next advance in minimally invasi-
ve therapy is uterine artery embolization
(UAE). In the female genital tract, embo-
lotherapy for control of hemorrhage from
malignancy was first reported in 19793–5.
Pais reported successful embolotherapy
for postpartum hemorrhage in 1980, and
Rosenthal and Colapinto for postoperati-
ve vaginal hemorrhage in 19856,7. In the
early 1990s, Ravina started to use embo-
lization as a presurgical procedure to dec-
rease intraoperative bleeding during fib-
roid surgery8,9. The embolization as a
primary therapy for uterine fibroids was
first performed in the 199510,11. Since
then, several large series have been re-
ported12–18. The aim of our study was to
evaluate the safety and efficacy of uterine
fibroid embolization in patients with symp-
tomatic uterine fibroids.
Subjects and Methods
The procedure was performed in 69
patients with symptomatic uterine fib-
roids in the Clinical Hospital Split. All
patients were premenopausal women scre-
ened by a gynecologist with the use of a
designed care algorithm. A detailed gyne-
cologic history was obtained from each
patient, followed by a detailed descripti-
on of the procedure including a discussion
of its potential risks. They were without
genital infection, other pelvic masses and
without malignancy. Eligibility was not
restricted by age, fibroid size, fibroid loca-
tion, or previous surgical therapy. Women
desiring children were excluded from the
study.
Preprocedural testing consisted of the
following laboratory tests (complete blood
count, blood urea nitrogen, creatinine,
prothrombin time) and magnetic reso-
nance imaging of the uterus. The patients
were informed that there might be very
significant pain for up to a few days after
the procedure, and that there might be as-
sociated nausea and vomiting. They were
admitted to department of gynecology the
day before the procedure, and they were
with an empty stomach. A 5F angiograp-
hic catheter was placed under local anes-
thesia in the right femoral artery and ad-
vanced over the aortic bifurcation to the
contralateral internal iliac artery. Digital
angiography was performed to identify
the origin of the uterine artery, and there-
after, the left uterine artery was cathete-
rized with 3F microcatheter. Once the
microcatheter was deep within the uteri-
ne artery, polyvinyl alcohol, 350–500 mm
sized particles (Ivalon, Nycomed, Paris),
were injected until there was complete
stasis of flow. The 5F catheter was then
maneuvered into the ipsilateral internal
iliac artery, and the embolization proce-
dure was repeated in the ipsilateral uter-
ine artery. All catheters were removed
and groin pressure was applied for 10 to
15 minutes, thus completing the procedu-
re. The goal of the therapy was to occlude
the uterine artery branches that supply
only the fibroid tumors and spare the nor-
mal myometrial vessels. The arteriog-
rams obtained after embolization revea-
led complete occlusion of the branches
supplying the fibroids. After the emboli-
zation procedure, patients are placed at
bedrest for 12 hours and are monitored
for bleeding and hematoma formation at
the arterial puncture sites. The Foley cat-
heter was removed 12 hours after the
procedure, and the patients had received
intravenous medications for nausea, vo-
miting or pain control. The majority of
the patients (58) left the hospital next
day after the procedure. The patients
completed outcome questionnaires follow-
ing their treatment. They were asked
whether their symptoms resolved comple-
tely, improved, remained unchanged or
deteriorated. All patients with successful
procedures underwent follow-up gyneco-
logic examination within 2 weeks of the
procedure and at regular intervals (ap-
proximately 6 weeks, 3 months, 6 months
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and 12 months). The patients with suc-
cessful procedures were evaluated at 3, 6
and 12 months after the embolization wi-
th magnetic resonance imaging. Measu-
rements of the uterus and fibroids were
obtained. Uterine volume and volume of
the dominant fibroid were calculated.
The percent volume reduction was calcu-
lated for each patient.
Mean values were expressed as arith-
metic mean. For comparisons of metric
variables Student's t-test was used.
Results
They were sixty five (94%) successful
uterine artery embolizations, but four
(6%) procedures were technically unsuc-
cessful; three of the patients underwent
unilateral embolization because of mal-
formed vessels and one of them had aller-
gic reaction to contrast medium. We ex-
cluded from statistical data processing
unsuccessful procedures. Clinical charac-
teristics are summarized in Table 1. The
mean patient age was 43.8 years.
The mean body mass was 67 kg and
height was 168 cm. All women had chil-
dren; range was one to four. The majority
of patients (58) went home on the day af-
ter procedure, and rest were admitted to
the hospital within the first week after
the procedure (range 1 to 7 days). Dura-
tion of hospitalization was on average 1.4
days. The mean procedure time was 37
minutes; range 26 to 81 minutes.
Table 2 summarizes the rate of regres-
sion of uterine and dominant fibroid volu-
mes.
Mean duration of clinical and magne-
tic resonance follow-up for all women was
atleast 12 months. Table 2 shows the
summary statistics for the uterine and
dominant fibroid volume prior to the pro-
cedure and the subsequent, 3 months, 6
months, and 12 months after the proce-
dure. Median uterine volume decreased
by 38%, 57%, and 61% after 3, 6 and 12
months after embolotherapy, respectively.
Comparison of the regression of preproce-
dural and final uterine volume revealed
statistical significance (p<0.01). Median
dominant fibroid volume decreased by 46%,
61%, and 66% after 3, 6 and 12 months
from preprocedure values, respectively.
The quantum regression of pretreatment
to final dominant fibroid volume also re-
vealed statistical significance.
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TABLE 1
CHARACTERISTICS OF PATIENTS WITH
SUCCESSFUL PROCEDURES (N = 65)
Mean Range
Age (years) 43.8 34–51
Weight (kg) 67.0 56–82
Height (cm) 168.0 157–181
Parity (number) 2.2 1–4





RATE OF REGRESSION OF UTERINE AND DOMINANT FIBROID VOLUME DETERMINED
BY MAGNETIC RESONANCE SCANNING (N = 65)
FOLLOW – UP (months)
0 3 6 12 p-level*
Uterine volume (cm3) 862 535 (–38%) 370 (–57%) 336 (–61%) <0.01
Dominant fibroid volume (cm3) 388 212 (–46%) 154 (–61%) 132 (–66%) <0.01
* t-test
Table 3 shows the experience of the
patients with the outcome of the procedu-
res.
Seventy-two percent of the patients
were without symptoms of menorrhagia,
hypermenorrhea, pelvic pain or pressure,
3 months after embolization. Twenty –
two percent of patients had moderate im-
provement in their symptoms, and only
three percent of the women had only im-
provement. Two patients (3%) were slight-
ly dissatisfied with the outcome of the
procedure, as they had not had any chan-
ge in their symptoms. No patient had
markedly worse and no serious complica-
tions were observed. Approximately twen-
ty percent of the patients developed fever
and malaise in the first 7 to 14 days. Also,
approximately one third of women com-
plained of a persistent mucoid vaginal
discharge for up to 3 months after proce-
dure. This had resolved spontaneously in
all women. Five women have become
amenorrheic for some time after emboli-
zation, but all these patients resumed
menses within 6 months.
Discussion
A method of nonsurgical treatment of
uterine fibroids involving embolization of
the uterine arteries, has been discussed.
This technique, performed by interven-
tional radiologists, has long been used in
cases of intractable postoperative and
postpartum hemorrhage3–7. Its applica-
tion for reducing the size of benign uteri-
ne tumors has recently been reported by
some authors8–18. The procedure is rapid,
with most procedures taking less than 1
hour. It can be performed independent of
the size of the uterus, in contrast to lapa-
roscopic procedures, which are often diffi-
cult in an abdomen filled with fibroids. In
addition, all fibroids are treated simulta-
neously.
All authors who have published a series
of any size, have reported essentially iden-
tical outcome statistics3,10–18. Our initial
experience parallels that of others3,10–17,19.
Symptoms were substantially improved
in similar percentages, patient satisfac-
tion with the procedure was high, and
there were few complications requiring
therapy. The high rate of women's satis-
faction with uterine artery embolization
in our study was directly related to their
improvements in menorrhagia and to the
reduced influence on their life.
The uterine and dominant fibroid vol-
ume reduction seen in our study at follow –
up after uterine artery embolization was
similar to that reported by others3,10–17,19.
A time course for uterine and dominant
fibroid volume reduction after emboliza-
tion has not been determined, but our
study and other studies have shown the
most reduction after six months3,9,10,12–19.
Overall, uterine artery embolization
for the treatment of uterine fibroids is mi-
nimally invasive, preserves the uterus,
and requires shorter hospitalization and
recovery times than hysterectomy and
myomectomy. Successful pregnancy after
this procedure has been reported9,10,20.
The overall effect of this procedure on fu-
ture fertility and childbearing remains
the greatest unknown. We agree with se-
veral authors that embolization is not a
first – line treatment for patients who de-
sire fertility. Ongoing follow – up, how-
ever, is needed to evaluate the long term
efficacy of this therapy.
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TABLE 3
EXPERIENCE OF THE PATIENTS (N = 65)
N (%)
Markedly improved 49 (72)
Moderately improved 14 (22)
Slightly improved 2 (3)
Unchanged 2 (3)
Worse 0
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TERAPIJA UTERINIH FIBROIDA EMBOLIZACIJOM UTERINE ARTERIJE
S A @ E T A K
Embolizacija uterinih arterija minimalno je invazivan zahvat, u usporedbi s histe-
rektomijom, klasi~nom ili laparoskopskom enukleacijom mioma. Cilj ovog rada bio je
procijeniti korist i uspje{nost embolizacije uterinih arterija i mi{ljenje pacijentica o
zahvatu. Nakon ginekolo{ke obrade u {ezdeset devet `ena u prijemenopauzi izvr{ena
je embolizacija uterinih arterija. ^etiri zahvata bila su neuspje{na; u triju `ena izvr{e-
na je jednostrana embolizacija poradi malformiranih krvnih `ila, jedna je imala aler-
gijsku reakciju na kontrastno sredstvo. Od 69 pacijentica 58 ih je napustilo bolnicu sli-
jede}i dan poslije zahvata, a ostalih 11 tijekom prvog tjedna. Kontrolni pregledi nakon
3, 6 i 12 mjeseci pokazali su zna~ajno smanjenje veli~ine maternice i mioma i zna~ajno
pobolj{anje krvarenja. Dakle, prema ovom izvje{}u, embolizacija uterinih arterija je
uspje{an, minimalno invazivan na~in lije~enja mioma koji sa~uva maternicu i uklju~u-
je kra}u hospitalizaciju i kra}e vrijeme oporavka u odnosu na kirur{ko lije~enje.
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